Eli Lilly’s weight loss drug Zepbound, priced around $1,000 monthly, is inaccessible for many, leading some like 29-year-old Willow Baillies to use a compounded version of its active ingredient, tirzepatide, costing approximately $350. This alternative has significantly improved her health and aided in weight loss. However, the FDA recently ended the tirzepatide shortage, which may restrict access to compounded versions. Patients fear the financial impact, as insurance often doesn’t cover Zepbound. Some may resort to unsafe DIY methods for medication, highlighting a broader problem with drug affordability and access in the U.S., especially for treatments related to obesity and chronic illnesses.
